Blog

New Biosimilar Era | FDA’s Biggest Shift

Chief Pharmacist

FDA has delivered the most consequential policy change in two decades, a shift that fundamentally transforms how our industry will ...

Common Technical Document (CTD)

Chief Pharmacist

The Common Technical Document (CTD) is one of the most significant harmonisation achievements in global regulatory science. Before CTD, every ...

Inspection Readiness | From Audit Week to Always-On

Chief Pharmacist

I have lost count of how many times I have seen teams go into panic mode the week before an ...

Understanding D50 in Particle Size Distribution of API – Why It Matters!

Chief Pharmacist

In pharmaceutical development, Particle Size Distribution (PSD) is a critical quality attribute—especially for Active Pharmaceutical Ingredients (APIs). Among the PSD ...

API Particle Size Distribution (PSD) Matters in Generic Formulations

Chief Pharmacist

In generic oral solid dosage forms, API particle size distribution is not just a physical parameter—it is a critical material ...

When is a Clinical Endpoint Bioequivalence Study Required?

Chief Pharmacist

In the world of generic drug development, clinical endpoint bioequivalence (BE) studies come into play when traditional PK-based BE studies ...

BCS-Based Biowaiver vs. In Vivo Bioequivalence Study

Chief Pharmacist

When developing a generic drug for global markets, one critical decision can save months of development time and significant costs ...

Understanding Non-Sink Conditions in Dissolution Testing

Chief Pharmacist

In pharmaceutical R&D, dissolution testing plays a vital role in predicting drug release and bioavailability. While most studies are conducted ...

Discriminatory Dissolution & Q-Point Specification – The Connection

Chief Pharmacist

A dissolution method with discriminatory power ensures it can detect critical differences in formulation or process that may impact drug ...

API/Drug Substance Selection in Generic Development – Key Points

Chief Pharmacist

With 15 years of experience in formulation research and technology transfer, I’ve seen how critical it is to finalize the ...

Reactive Impurities in Pharmaceutical Excipients

Chief Pharmacist

Reactive impurities in pharmaceutical excipients are often overlooked, yet they can have a serious impact on drug product stability and ...

API Impurity Specification

Chief Pharmacist

In making medicines, setting impurity limits for the Active Pharmaceutical Ingredient (API) is a key step to ensure quality and ...

12313 Next